Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients and works by selectively blocking β1‑adrenergic receptors while promoting nitric‑oxide mediated vasodilation. It is marketed within the European Union and is available only by prescription.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation for each batch.

Nebivolol is a selective β1‑blocker used in cardiovascular therapy to lower blood pressure and improve heart function. - Hypertension: reduces systolic and diastolic pressure, decreasing cardiovascular risk. - Heart failure: enhances left‑ventricular ejection fraction and alleviates symptoms in patients with reduced ejection fraction. - Isolated systolic hypertension in the elderly: provides effective blood‑pressure control with a favorable heart‑rate profile.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially after standing. - Fatigue or tiredness: often transient. - Bradycardia: heart rate slower than normal. - Nausea: occasional gastrointestinal upset. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Severe bradycardia: may require medical attention. - Symptomatic hypotension: marked drop in blood pressure. - Heart block or AV conduction disturbances. - Bronchospasm: especially in patients with reactive airway disease. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzymes.

Before initiating therapy, consider the following safety measures. - Blood pressure monitoring: check baseline and periodic readings. - Heart rate monitoring: observe for excessive bradycardia. - Renal impairment: dose adjustment may be required. - CYP2D6 poor metabolizers: consider alternative therapy. - Concomitant beta‑blockers: avoid additive cardiac depression. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Nebivolol can interact with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Combined use with other β‑blockers: risk of excessive bradycardia and hypotension. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma concentrations. - Calcium‑channel blockers affecting AV node (verapamil, diltiazem): additive cardiac depression.

Moderate Interactions (Monitor Closely): - Non‑selective β‑blockers: monitor heart rate and blood pressure. - Diuretics: may enhance antihypertensive effect, watch for volume depletion. - ACE inhibitors or ARBs: monitor for additive blood‑pressure lowering. - Antihyperglycemics: nebivolol may mask hypoglycemia symptoms.